DETECT

Condition: Diabetes, pancreatic cancer, pancreatic diseases

Eligibility

Key Inclusion Criteria

  • At least 40 years old; less than 85 years old
  • Must have a diagnosis of one of the following:
    • New onset diabetes in subjects with pancreatic cancer (PDAC)
    • New onset diabetes in subjects with chronic pancreatitis
    • New onset diabetes in subjects without pancreatic disease 
    • Long-standing Type 2 diabetes without pancreatic disease
    • Long-standing diabetes in subjects with PDAC
    • Long-standing diabetes subjects with chronic pancreatitis
    • Non-diabetic subjects with PDAC
    • Non-diabetic subjects with chronic pancreatitis
    • Non-diabetic control subjects without pancreatic disease

Key Exclusion Criteria

  • Must not have any significant medical illnesses (including diabetes) that cannot be adequately controlled with appropriate therapy or would compromise the patient’s ability to tolerate study interventions
  • Diabetes not stable enough to permit holding of diabetes medications
  • Taking higher doses of insulin (≥0.5 unit/kg/day)

Full Study Name

CPDPC16-04: Evaluation of a Mixed Meal Test for Diagnosis and Characterization of Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) (IRB no. 50528)

This study focuses on patients who have chronic pancreatitis, pancreatic cancer, or no known pancreas disease. It is now recognized that a small portion of the population with diabetes have an underlying problem with their pancreas, such as chronic pancreatitis (when the pancreas is swollen and irritated all the time and affected by scarring) or pancreatic cancer, as the cause of their diabetes. Currently, there is no test to identify the small number of patients who have diabetes caused by a primary problem with their pancreas. The purpose of this study is to develop a blood test to distinguish various causes of diabetes. To this end, researchers will enroll a range of patients; most have developed diabetes within the last 3 years, but the study will also enroll a small number of patients with long-term diabetes and normal blood sugars for comparison. Participants will be asked to complete a questionnaire regarding their personal and family history, and a series of blood samples will be collected prior to and for 2 hours following consumption of a liquid nutritional supplement called Boost.

Principal Investigator

Mark Goodarzi, MD

Contact
Emily Hautamaki
Phone: 310-423-0347 
Email: emily.hautamaki@cshs.org